Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK)
analyses and physiologically based biopharmaceutics model (s)(PBBM (s)) have been …

Oral siponimod (Mayzent®), a next-generation, selective sphingosine 1-phosphate receptor
(S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. In
recent years, many disease-modifying therapies (DMT) have been approved for MS …

Physiologically-based pharmacokinetics (PBPK) modeling is a robust tool that supports drug
development and the pharmaceutical industry and regulatory authorities. Implementation of …

Pharmacogenomic testing interrogates germline sequence variants implicated in
interindividual drug response variability to infer a drug response phenotype and to guide …

Background Sphingosine-one phosphate receptor (S1PR) modulation inhibits S1PR1-
mediated lymphocyte migration, lesion formation and positively-impacts on active multiple …

Multiple sclerosis is a chronic inflammatory neurological disease, and siponimod (Mayzent)
is the first oral treatment option for adult patients with secondary progressive multiple …

Introduction Fingolimod was the first oral disease-modifying treatment approved for
relapsing-remitting multiple sclerosis (MS) that serves as a sphingosine-1-phosphate …

Abstract Tamsulosin, a selective\upalpha _ 1 α 1-adrenoceptor blocker, is commonly used
for alleviation of lower urinary tract symptoms related to benign prostatic hyperplasia …

Introduction A number of disease-modifying therapies have been approved for use in
relapsing-remitting multiple sclerosis (MS) in the past two decades. However, only few …